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Abstract
Objective Obsessive compulsive and related disorders are a collection of debilitating psychiatric disorders in
which the role of glutamate dysfunction in the underpinning neurobiology is becoming well established. N-
acetyl cysteine (NAC) is a glutamate modulator with promising therapeutic effect. This paper presents a
systematic review of clinical trials and case reports exploring the use of NAC for these disorders. A further
objective was to detail the methodology of current clinical trials being conducted in the area. Methods
PubMed, Web of Science and Cochrane Library Database were searched for human clinical trials or case
reports investigating NAC in the treatment of obsessive compulsive disorder (OCD) or obsessive compulsive
related disorders. Researchers with known involvement in NAC studies were contacted for any unpublished
data. Results Four clinical trials and five case reports/series were identified. Study durations were commonly
12-weeks, using 2,400?3,000 mg/day of NAC. Overall, NAC demonstrates activity in reducing the severity of
symptoms, with a good tolerability profile and minimal adverse effects. Currently there are three ongoing
randomized controlled trials using NAC for OCD (two adults and one pediatric), and one for excoriation.
Conclusion Encouraging results have been demonstrated from the few pilot studies that have been
conducted. These results are detailed, in addition to a discussion of future potential research.
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N-Acetyl Cysteine in the Treatment of Obsessive Compulsive and Related 
Disorders: A Systematic Review
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Jerome Sarris1,4
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Objective: Obsessive compulsive and related disorders are a collection of debilitating psychiatric disorders in which the role 
of glutamate dysfunction in the underpinning neurobiology is becoming well established. N-acetyl cysteine (NAC) is a glutamate 
modulator with promising therapeutic effect. This paper presents a systematic review of clinical trials and case reports exploring 
the use of NAC for these disorders. A further objective was to detail the methodology of current clinical trials being conducted 
in the area.
Methods: PubMed, Web of Science and Cochrane Library Database were searched for human clinical trials or case reports 
investigating NAC in the treatment of obsessive compulsive disorder (OCD) or obsessive compulsive related disorders. 
Researchers with known involvement in NAC studies were contacted for any unpublished data.
Results: Four clinical trials and five case reports/series were identified. Study durations were commonly 12-weeks, using 
2,400-3,000 mg/day of NAC. Overall, NAC demonstrates activity in reducing the severity of symptoms, with a good tolerability 
profile and minimal adverse effects. Currently there are three ongoing randomized controlled trials using NAC for OCD (two 
adults and one pediatric), and one for excoriation.
Conclusion: Encouraging results have been demonstrated from the few pilot studies that have been conducted. These results 
are detailed, in addition to a discussion of future potential research.
KEY WORDS: Obsessive-compulsive disorder; Trichotillomania, acetylcysteine; Glutamate; Review, systematic.
INTRODUCTION
Obsessive compulsive disorder (OCD) is a debilitating 
neuropsychiatric disorder which is suggested to affect 
1-2% of the population.1,2) OCD has previously been cat-
egorised as an anxiety disorder; however, the American 
Psychiatric Association via the Diagnostic and Statistical 
Manual of Mental Disorders-version 5 (DSM-5) now as-
signs OCD with its own classification (American 
Psychiatric Association, 2013). This distinction is war-
ranted given OCD’s unique neurobiology,3,4) clinical pre-
sentation and targeted cognitive behavioural therapies 
compared with other anxiety disorders.5) Although anxi-
ety appears to be a prominent symptom of OCD, anxiety is 
ubiquitous amongst diverse psychopathologies, and is on-
ly one marker of OCD severity.6) Hoarding, excoriation 
and trichotillomania (TTM) were previously included in 
the OCD spectrum; however, in the DSM-5, they are now 
categorised as obsessive compulsive related disorders 
(OCRD). This segregation stems from disparities between 
gender distribution and age of onset, comorbidities as well 
as the variations of neurobiology and neuropsychology.7,8) 
In addition, the efficacy of pharmacotherapies used in 
OCD has not yielded the same results in TTM patients, 
further supporting differing underlying neurobiology in 
these disorders.9) However, OCRD and OCD share similar 
clinical presentations, characterised by inappropriate and 
excessive repetitive behaviours and dysregulation of in-
hibitory control processes, which suggests that some com-
ponents of their pathophysiology may be similar.10,11) The 
commonalties in the neurobiology underlying these dis-
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orders are yet to be elucidated.
Despite extensive investigations into the neuro-
biology of OCD, its precise etiology remains unclear. 
Genetic polymorphisms,12-14) autoimmune processes,15) 
infections,16) inflammatory and oxidative stress17,18) and 
abnormalities of neurotransmission within the brain19,20) 
have all been suggested as underlying causes and/or con-
tributing factors.
Selective serotonin reuptake inhibitors (SSRIs) are con-
sidered to be one of the first-line interventions for OCD.5) 
Despite demonstrating positive effects in several in-
stances,21) it is estimated that 40% of patients do not ach-
ieve a clinical response from these medications, nor other 
augmentation strategies.22) In addition, SSRIs are often re-
quired at significantly higher doses than those used for de-
pression to obtain clinical benefits, and complete func-
tional recovery is rare.21,23) Such a varied response rates to 
SSRIs may in part be explained by the heterogeneous neu-
robiology associated with the disorder, but may also be 
due to individual variances in drug absorption and 
metabolism. SSRIs, particularly at the required higher 
doses, are associated with adverse effects such as anxiety, 
insomnia, nausea, diarrhea, constipation, dizziness, seda-
tion and sexual dysfunction.21,24) Our own clinical experi-
ence has shown that the severity and nature of adverse ef-
fects associated with the use of SSRIs can often lead to 
treatment discontinuation, further demonstrating the need 
for more targeted therapeutics.
A growing body of evidence suggests that abnormal-
ities within the cortico-striato-thalamic-cortical (CSTC) 
circuits are one of the key factors underlying the patho-
physiology of OCD.25,26) Specifically, hyperactivity with-
in the orbitofrontal cortex, anterior cingulate and ven-
tromedial striatum has been associated with OCD 
behaviour.27,28) Glutamate is the primary neurotransmitter 
within the CSTC, and evidence suggests that abnormal glu-
tamate metabolism is apparent in patients with OCD.29,30) 
Significantly higher levels of glutamate have been found 
in the cerebral spinal fluid and various regions of the brain 
including the right caudate and orbitofrontal cortex of 
treatment refractory OCD patients.15,31,32) However re-
duced concentrations were evident in the anterior cingu-
late in a sample of women with OCD, and were correlated 
with symptom severity.31) In addition, high levels of gluta-
mate result in excitotoxicity and oxidative stress33) and ox-
idative stress has been detected in serum samples from 
those diagnosed with OCD, as evidenced by lipid perox-
idation and alterations to antioxidant systems.17,18,34) In ad-
dition, higher levels of oxidative stress appear to correlate 
with symptom severity.35) Whether these findings are a 
cause or consequence of OCD pathophysiology, is yet to 
be identified. Given glutamate’s role in mediating fear re-
lated memory,36) abnormalities in this neurotransmitter’s 
activity may play a role in the poor cognitive processing 
and doubt in OCD. Glutamate’s role in the CSTC, memo-
ry and cognition as well as its pro-oxidant properties sup-
ports its suggested role in the pathophysiology of OCD. 
Although the role of glutamate in the neurobiology of 
OCRD is yet to be elucidated in brain imaging studies,37) 
the ability of glutamate modulating agents to regulate im-
pulse control, a characteristic of OCRD and substance 
abuse,38) is becoming increasingly apparent.39-41) Thus, the 
use of glutamate-modulating agents is of growing interest 
for OCRD.
Glutamate-modulating agents which have been inves-
tigated for OCD and OCRD include riluzole, memantine, 
topiramate, lamotrigine and glycine; however, mixed re-
sults have been reported.42) More recently, N-acetyl cys-
teine (NAC), a derivate of the amino acid L-cysteine, has 
been explored as a potential therapy for OCD and OCRD 
(Fig. 1). With greater bioavailability, stability, solubility 
and resistance to oxidation upon consumption than L-cys-
teine, NAC has demonstrated neurochemical, antioxidant, 
antiinflammatory, mucolytic and hepatoprotective acti-
vity.43,44) An advantage of NAC in comparison to other 
glutamatergic pharmaceuticals, is that it is available 
over-the- counter without prescription, and thus repre-
sents a more affordable and accessible treatment option. 
Further, NAC has also demonstrated efficacy in amelio-
rating oxidative stress (discussed below), so could provide 
benefits to brain health that are in addition to normal-
isation of glutamatergic transmission.44)
After oral administration, NAC undergoes deacetyla-
tion in the liver to form cysteine, which is used as substrate 
for glutathione (GSH) production.45) Unconverted cys-
teine enters the blood stream; however, reports on the abil-
ity of cysteine, or the parent NAC compound, to cross the 
blood brain barrier (BBB) are contradictory.46-48) Regard-
less, detection of increased GSH levels in the brain were 
evident after administration of NAC to rats.49) More re-
cently, patients with major depressive disorder (MDD) 
supplemented with NAC were found to have increased 
levels of NAC metabolites (necessary for GSH pro-
duction) in the anterior cingulate cortex detected by pro-
ton magnetic spectroscopy.50) These studies suggest that 
NAC does initiate effects in the brain. It has been postu-
lated that cysteine may cross the BBB via a sodium-de-
pendent transport system where it is converted into cys-
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Fig. 1. Consort chart.
tine, the di-sulfide derivative of cysteine.51) High levels of 
cystine stimulate the exchange of intracellular glutamate 
for cystine through the cystine-glutamate antiporter, there-
by elevating non-synaptic glutamate.52,53) This process ac-
tivates the metabotropic glutamate receptors (mGluR2/3) 
on presynaptic neurons, responsible for inhibiting the syn-
aptic release of glutamate and thereby restoring ex-
tracellular glutamate levels in the nucleus accumbens.54,55) 
Regulating this exchange system has been shown to im-
prove impulse control and reduce addictive behaviour 
both pre-clinically and clinically.40,41,56,57) Intracellular 
cystine can then be reduced back to cysteine and used for 
GSH production, the potent and most abundant endoge-
nous antioxidant in the body.33,58)
A clearer understanding of the pharmacokinetics and 
pharmacodynamics of NAC has prompted clinical inves-
tigations of this nutraceutical as a glutamate-modulating 
therapeutic agent for psychiatric conditions, including ad-
dictive behaviour (such as gambling, cocaine, nicotine 
and marijuana use),41,59,60) bipolar disorder,61,62) schizo-
phrenia,63,64) and autism.65) The ability of NAC to modu-
late factors associated with OCD and OCRD, such as the 
regulation of extracellular glutamate and the reduction of 
oxidative stress (through direct radical scavenging and in-
creasing GSH activity), indicates that this agent may be an 
effective treatment for OCD and OCRD.44) Animal stud-
ies have provided some support of this hypothesis. In a 
mouse model of OCD involving marble burying behav-
iour, NAC dose-dependently decreased burying behav-
iour independent of locomotor activity.66)
Pilot studies and case reports of NAC in the treatment 
OCD and OCRD have been published.39,67,68) Despite one 
generalised nutraceutical69) and one complementary med-
icine review70) for OCD and OCRD to date, there has been 
no specialised review collating the current clinical evi-
dence specifically for NAC in OCD or OCRD. This paper 
addresses this deficit by providing a systematic review of 
the evidence of published studies and current ongoing 
clinical trials.
METHODS
PubMed, Web of Science and the Cochrane Library 
Database were searched in up to March 20, 2014, using the 
search terms “trichotillomania” OR “hair pulling” OR 
“hoarding” OR “hoard” OR “excoriation” OR “skin pick-
ing” OR “nail biting” OR “impulse control disorder” OR 
“obsessive compulsive disorder” OR “OCD” OR 
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Fig. 2. Chemical structure of N-acetyl cysteine.
“OCRD” OR “obsessions” OR “compulsions” OR 
“obsessive compulsive related disorder” AND “N-ace-
tylcysteine” OR “n-acetyl-cysteine” OR “nacetylcys-
teine” OR “cystine” OR “n acetylcysteine” OR “n acetyl 
cysteine” OR “N-acetyl-L-cysteine”. Academics and re-
searchers with known involvement in NAC research were 
also contacted in an attempt to obtain any unpublished 
literature. Searches of the Australian and New Zealand 
Clinical Trial Registrar (ANZCTR) and Clinical-
Trials.gov were also included, to determine any current or 
upcoming NAC OCD/OCRD clinical trials. 
Inclusion criteria consisted of human clinical trials or 
case reports - open label or controlled, involving DSM-IV 
or DSM-5 diagnosed OCD or OCRD in which NAC was 
prescribed. Conditions with very similar clinical charac-
teristics to OCD and OCRD also warranted inclusion. 
While both monotherapy and adjunctive trials were open 
for inclusion, to date there is only data available on ad-
junctive studies of NAC. There was no restriction on gen-
der, age, treatment resistance, symptom severity, dosage 
of NAC or study design, as very limited data in the area 
was suspected. OCRD studies were also included, as they 
are now considered to be within the obsessive compulsive 
paradigm in the DSM-5. Given the similarity in symptoms 
between the two disorders (e.g., repetitive behaviours), 
we wanted to explore whether efficacy of NAC would be 
similar across both OCD and OCRD, as well as other con-
ditions presenting with similar features.
Analysis of the Data
Data from the clinical trials which included a control 
group were used to calculate an effect size as Cohen’s d by 
first subtracting the differences in scores between the 
baseline and post-treatment endpoint for the intervention 
(or between placebo and intervention), then dividing this 
by the pooled standard deviation at baseline. For data 
without a control group, we provide a descriptive over-
view of the findings. The term “significant” was used for 
a p value of <0.05.
RESULTS
Overview
An initial search returned 47 papers, of which 11 met in-
clusion criteria (Fig. 2). Thirty-two papers were excluded 
on the basis of being either review articles (n=16), treat-
ment protocols for OCD or OCRD (n=5), preclinical stud-
ies (n=4) or neurobiological investigations (n=7). Of the 
remaining 15, four clinical trials were excluded, as they 
did not investigate NAC for OCD, OCRD or similar 
conditions. This left four randomized, double blind, place-
bo controlled trials, one open label pilot study and six case 
reports. The mean trial length or length of supplementa-
tion with NAC was 13 weeks (range, 8-28 weeks) with the 
mean number of participants being 19 (range, 1-44) with 
a mean age of 30 years (range, 5-68 years). The mean of 
the peak NAC dose used in the studies was 1,587 mg/day 
(range, 800-3,000 mg/day). Sample sizes varied greatly 
due to the inclusion of case reports. Co-morbidities and 
additional treatments utilised by the participants were un-
specified in some of the studies. No unpublished literature 
was available for inclusion.
N-Acetyl Cysteine for Obsessive Compulsive Disorder
Case reports
One of the first published findings of NAC in the treat-
ment of OCD was a case study reported by Lafleur and 
colleagues,67) published in 2006. A 58 year old, peri-
menopausal woman was supplemented with NAC which 
was titrated from 600 mg to 3,000 mg daily over six 
weeks, and continued at the latter dose for the remaining 
six weeks. A dramatic drop in symptom severity was de-
tected in the first week as determined by the Yale Brown 
Obsessive Compulsive Scale (Y-BOCS), with baseline 32 
reduced to 24. However, this may be attributable to psy-
chological factors associated with clinician interaction 
rather than pharmacological effects of NAC. A steady de-
crease continued from week two to week five, and despite 
fluctuations in symptom severity observed between 
weeks five and 10, there was an overall trend of improve-
ment over the 12 weeks (Y-BOCS score of nine at end-
point). Of note, the patient’s Hamilton Rating Scale for 
Depression (HAM-D) score also decreased significantly 
over the 12 weeks, from a baseline score of 14 to an end-
point score of five. After her discharge from the hospital at 
the end of the 12 weeks, NAC therapy (3,000 mg/day) was 
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maintained and a 2-month follow up demonstrated con-
tinued improvements in OCD symptoms. However, it is 
unclear from this case report whether symptomatic im-
provement at follow up was assessed based on a Y-BOCS 
score or self/clinician-reporting. Although the significant 
improvement in this patient’s OCD suggests a promising 
application for the use of NAC in others, great caution 
needs to be exercised in interpreting case reports.
In contrast, a more recent series of six retrospective 
case reports concluded little efficacy of NAC for OCD.71) 
All six patients were considered to have severe OCD 
(Y-BOCS score of 29.3±4.3) and were treatment-resistant 
(i.e., unresponsive to at least two first line pharmaco-
therapies). The NAC dose was titrated to 3,000 mg/day, 
however titration lengths for each patient were not con-
trolled, therefore the length of time each patient received 
the 3,000 mg/day dose of NAC was unidentified. 
However, five out of six patients reported to be on 3,000 
mg/day for four weeks. NAC was used adjunctively in this 
series and all patients were receiving pharmacotherapies 
(as outlined in Table 1) at doses which had been stable for 
a minimum of eight weeks prior to supplementation with 
NAC. The only patient who demonstrated a modest re-
sponse to NAC in this series began with ‘moderate’ OCD 
severity (Y-BOCS of 26 baseline, 17 at endpoint) and 
MDD was the only identified comorbidity, as compared to 
other patients who experienced multiple co-morbidities. 
This response is comparable to previous studies involving 
cohorts of OCD patients with similar symptom severities 
to this patient67,68) and suggests that individuals with more 
severe and chronic OCD may be treatment-resistant to 
NAC at the 3,000 mg/day dose for this length of time. 
Interestingly, the two patients who were non-responsive to 
glutamatergic medications (topiramate and lamotrigine) 
did not show an improvement on NAC, but instead dem-
onstrated a worsening in their symptom severity accord-
ing to their Y-BOCS score. This highlights the increas-
ingly accepted concept of the heterogeneous nature of 
OCD neurobiology and suggests that NAC may in-
effective against glutamate-independent presentations of 
OCD. The NAC dosage and treatment regimen associated 
with this case report is questionable. Patients were relied 
upon for the purchase and consumption of the correct dose 
of NAC. No method was employed by researchers to mon-
itor adherence to the correct treatment regimen. For exam-
ple, remaining pills were not counted and the quality of the 
NAC was not assessed. Thus, the low response rate re-
ported could be attributable to poor patient compliance, or 
use of potentially substandard quality NAC products. For 
these reasons, and the small sample size of the paper, the 
use of NAC cannot be discredited in a larger cohort until 
further clinical trials are conducted.
Clinical trials
To our knowledge, there has been only one randomised 
clinical trial completed assessing the use of NAC in the 
treatment of OCD.68) This 12-week study was conducted 
in Iran where NAC was titrated from 600 mg/day and dou-
bled weekly to reach a maximum dose of 2,400 mg/day (at 
week-3). This dose was maintained for the remaining nine 
weeks of the trial. Symptom severity was assessed by the 
Y-BOCS and Clinical Global Improvement (CGI) scales 
at four-week intervals. The mean age of study participants 
was 30.93 years (range, 23-44 years) and the cohort con-
sisted predominantly of women (75%). The treatment 
group (n=20) demonstrated a significant effect over place-
bo (n=19) for ameliorating OCD symptoms according to 
the Y-BOCS. A gradual and continual decrease in symp-
tom severity was evident from week-4, with the NAC 
showing significance over placebo from week-8 onwards. 
Although a promising result, there are various limi-
tations associated with this study. Ten participants in the 
treatment group recorded a full clinical response, defined 
as a 35% or greater reduction in their Y-BOCS score com-
pared to baseline. The remaining nine patients’ response 
rates were not specified, and can be assumed to be less 
than 35%. This further raises the possibility that NAC may 
be effective only in a subset of OCD patients. Co-morbid-
ities were not noted by the researchers, and if recorded, 
may have identified whether NAC was more beneficial in 
patients with less complex presentations, as postulated by 
the van Ameringen et al.’s case series.71) The severity of 
this particular group of OCD participants was moderate 
(mean Y-BOCS=27), representing a select population of 
OCD patients. Additionally, a longer clinical trial may 
have determined if NAC efficacy would have continued, 
as has been shown in clinical trials involving individuals 
with bipolar disorder (in the depressive phase) who expe-
rienced continual improvements in their depressive symp-
toms occurring over a 24 week period.61)
N-Acetyl Cysteine for Obsessive Compulsive Related 
Disorders
Case reports
Several case reports exist for NAC in the treatment 
OCRD, including TTM, pathological nail biting and ex-
coriation (Table 2). Promising results were obtained from 
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case report of Rodrigues-Barata et al.72) involving two fe-
males (aged 23 years and 19 years) with chronic TTM, 
who were non-responsive to previous psychotherapy and 
SSRI medications. Both patients demonstrated complete 
regrowth of their hair within three months when supple-
mented with 1,200 mg/day of NAC. The authors noted 
that the positive results were maintained at a six-month 
follow up for the 23 year old, but did not specify if the 
NAC treatment was continued over this period. A follow 
up visit was not recorded for the 19 year old. Likewise, im-
provements were noted in another case report of a 40 year 
old female with TTM who was treatment-resistant to vari-
ous medications and psychotherapy. Within three weeks 
of supplementation on NAC 1,200 mg twice daily she 
ceased hair pulling behaviour and noticed reductions in 
the urges to do so.73) Another patient, a 28 year old male 
with chronic TTM and nail biting demonstrated sig-
nificant improvements on 1,800 mg/day NAC within two 
weeks. Of note, a return of symptoms was observed when 
the patient failed to comply with the dosing regime over a 
two week period. When taking the NAC consistently, he 
reported both the urge and thoughts to ‘indulge’ in these 
behaviours ameliorated, as well as the physical action of 
doing so.73) Excoriation symptom improvements have al-
so been demonstrated in another case report, with picking 
urges decreasing by 50% within a week of NAC supple-
mentation at 1,200 mg/day.73) Once the NAC dose was in-
creased to 1,800 mg/day, complete abstinence was ach-
ieved within two days and was maintained at a four month 
follow up whilst continuing treatment at this dose. A more 
recent case report from Silva-Netto et al.74) further high-
lights NAC’s beneficial effects for excoriation. This re-
port showed ‘major improvements’ in treatment resistant 
skin picking behaviours in three females who were sup-
plemented with 1,200-1,800 mg daily of NAC. Of inter-
est, one of the three women showed a relapse in picking 
behaviours when she discontinued the NAC and saw great 
improvements when it was reintroduced, demonstrating a 
direct correlation between NAC supplementation and 
symptom relief. Beneficial effects on nail biting were also 
detected in three patients participating in a clinical trial for 
bipolar disorder where NAC (1,000 mg twice daily) was 
used as an adjunctive strategy.75) A 46 year old female with 
bipolar disorder, episodes of psychosis and “life long” nail 
biting, reported a cessation of biting behaviour after two 
weeks of NAC supplementation. Cessation was main-
tained for the following seven months whilst remaining on 
the NAC as part of the study. A 44 year old female diag-
nosed with rapid cycling bipolar, also experienced 
“lifelong nail biting” behaviour. After four months, she 
noticed she was able to more consciously cease biting her 
nails after awareness that one nail had grown back 
strongly. The third in this case report series was a 46 year 
old male who had experienced manic and depressive epi-
sodes since 16 years of age, and obsessive thoughts con-
cerning exercise and diet. The patient had a longstanding 
habit of biting his nails and chewing the surrounding skin 
on his fingers. By the end of the 28-week trial, he reported 
a reduction in his nail biting, but was unaware when he 
first noticed this since his participation. Of interest with 
this case series, two participants noted that cessation of 
their nail biting was autonomous, the other was able to 
consciously alter her behaviour after noticing an initial 
improvement. The participants were not taking NAC spe-
cifically to improve their nail biting behaviour, nor were 
they informed that NAC could do so by the researchers. 
This enhances the strength of the results from the case ser-
ies and reduces the likelihood of a halo effect. As always, 
although case reports can demonstrate promising results, 
caution needs to be taken when applied to a larger 
population.
Clinical trials
Promising results were obtained from Grant and col-
leagues’ pilot research,39) published in 2009 (Table 3). 
This randomized, double blind, placebo controlled trial 
demonstrated that 2,400 mg of NAC per day was superior 
to placebo for reducing TTM symptoms in 44 adults, dis-
playing significance from week-9. Significant improve-
ments across all TTM scales, including self-reported 
(Massachusetts General Hospital Hair Pulling Scale) and 
clinician-rated scales (Psychiatric Institute Trichotill-
omania Scales), were demonstrated in the NAC group. Of 
note, the treatment group recorded no adverse effects 
throughout the duration of the trial, highlighting that NAC 
has a good tolerability profile and appears safe as an ad-
junctive therapy. However, despite noticeable improve-
ments reported by both patients and clinicians regarding 
TTM symptoms, Quality of Life Inventory, HAM-D and 
Hamilton Anxiety scales (HAM-A) did not record a sig-
nificant improvement over placebo. In addition, the 
Sheehan Disability self reported scale, showed only a mild 
effect size (Cohen’s d=0.42). However, only low-mild 
functional impairment and mood was detected at baseline 
in both groups. For example, HAM-D mean scores were 
3.68 in both, and HAM-A mean scores were 3.72 and 3.4 
in the control and treatment groups respectively. Despite 
NAC demonstrating promising results over placebo for 
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Table 4. Current N-acetyl cysteine (NAC) in Obsessive Compulsive Disorders (OCD) and Obsessive Compulsive Related Disorders: Clinical 
Trials













NA 3,000 Y-BOCS, HAM-D Terminated due to limited 
participants and funding
Bloch et al. 
(Yale University)
NCT01172275
Pediatric OCD patients 
(8-17 years of age)
12 Week 
RDBPCT











2016 3,000 Y-BOCS, DY-BOCS,  






Adult OCD patients 16 Week 
RDBPCT







Excoriation 12 Week 
RDBPCT
2014 3,000 Y-BOCS modified 
for PSP, SP-SAS
Currently recruiting
ACTRN, Australian New Zealand Clinical Trials Registry; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CGI-I, Clinical Global 
Impression Scale-Improvement; CGI-S, Clinical Global Impression Scale-Severity; CY-BOCS, Children’s Yale Brown Obsessive Compulsive 
Scale; DY-BOCS, Dimensional Yale Brown Obsessive Compulsive Scale; HAM-A, Hamilton Anxiety Rating Scale; HAM-D, Hamilton Depression 
Scale; MADRS, Montgomery Asberg Depression Rating Scale; NA, not applicable; NCT, National Clinical Trial; PAERS, Pediatric Adverse Events 
Rating Scale; PSP, pathological skin picking; RDBPCT, randomised, double-blind, placebo controlled trial; SP-SAS, Skin Picking Symptom 
Assessment Scale; Y-BOCS, Yale Brown Obsessive Compulsive Scale.
improving TTM in this study, it is important to note that 
44% (n=11) of patients in the treatment group did not re-
spond to NAC. This varied response rate may be due dif-
ferences in disorder neurobiology or drug pharmacoki-
netics and/or pharmacodynamics between patients. As 
suggested by Grant et al.,39) future investigations involv-
ing NAC for TTM should explore the various subtypes of 
TTM (e.g., autonomous versus conscious hair pulling as 
well as the presentations of co-morbidities) to identify pa-
tient subgroups likely to be most responsive to NAC, en-
abling a ‘tailored’ treatment approach for each patient.
More recently, NAC, titrated to a maximum dose of 
2,400 mg over four weeks, failed to show significance 
over placebo in 35 pediatric TTM patients (aged 8-17 
years).76) The authors noted that given that an improve-
ment was seen in both groups, particularly in the first few 
weeks of treatment, the regular supportive assessments by 
the clinicians (every two weeks) and adjunctive psy-
cho-education could have been responsible for strength-
ening the placebo effect. Differing pathophysiologies 
have also been suggested in pediatric TTM compared to 
adult TTM.77) The severity of the urge, the associated 
anxiety and frequency of these thoughts appears to in-
crease in adults, and perhaps NAC is more specific for this 
population as shown by Grant et al.39)
NAC has demonstrated significant improvements in re-
lieving skin picking behaviours in an open label pilot 
study involving 35 children and adults (aged 5-39 years 
old) with Prader-Willi Syndrome (PWS).78) PWS is a neu-
rodevelopmental disorder caused by chromosome ab-
normalities and presents with obsessive-compulsive 
behaviours.79) Although not considered an OCRD as per 
the DSM-5, skin picking is apparent in 80-95% of in-
dividuals with the syndrome80) and its similarities with 
OCD and OCRD warrants inclusion in this review. After 
12 weeks of NAC supplementation, ranging from 
450-1,200 mg, all participants showed a significant im-
provement in skin picking behaviours determined by le-
sion size, frequency and the presence of scarring versus 
open wounds. Seventy-one percent of participants had 
complete resolution of self-mutilating behaviours, the re-
maining 29% had lesions that were smaller in size and 
number and with signs of wound healing present, e.g., the 
presence of scabs and reduction in the number of open 
lesions. The NAC was tolerated extremely well amongst 
all participants and used adjunctively to various medi-
cations without negative interactions (Table 3). Only mild 
gastrointestinal upsets were reported, such as cramping, 
flatulence and diarrhea. These symptoms dissipated after 
the first few weeks of NAC supplementation.
NAC (800 mg/day) has been studied versus a placebo 
comparator for treating nail biting in a double blind, 
randomized trial of 25 children and adolescents, aged 6-18 
years old.81) The primary outcome was measured nail 
length and participants were seen before treatment, one 
month after baseline and two months thereafter. A statisti-
NAC in the Treatment of OCD and OCRDs 21
cally significant difference in nail length between the two 
groups occurred after the first month of treatment (p≤0.04). 
However, no between-group differences were seen after two 
months. While methodologically limited, the trial provides 
preliminary support of the efficacy of NAC in decreasing 
nail biting behaviour in children and adolescents.
Current NAC in OCD and OCRD Clinical Trials
Several clinical trials are currently underway investigat-
ing NAC for the treatment of OCD and OCRD (Table 4). 
Results from these studies may clarify the efficacy of 
NAC for these disorders. Studies are being conducted in 
several regions around the world, with trials in progress in 
Australia, the USA, the UK and Brazil. These, coupled 
with a previous clinical trial conducted in Iran,68) highlight 
the global interest in the potential use of NAC for OCD 
and OCRD. Longer treatment phases (16 weeks) are plan-
ned for the Sarris and Shavitt trials, which will be advanta-
geous in identifying the therapeutic efficacy of NAC (as 
results may be found after 8-10 weeks of use), and de-
termining if these effects are long lasting. In addition, cur-
rent trials are better powered. The new trials will involve 
both pediatric and adult patient groups and may allow for 
determination of differences in NAC efficacy between pa-
tient subpopulations. Shavitt et al. will explore the symp-
tom dimensions within their OCD participants (e.g., so-
matic obsessions and compulsions, aggressive obsessions 
and compulsions) using the Dimensional Yale-Brown 
Obsessive Compulsive Scale. This will potentially reveal 
if NAC is beneficial for particular presentations of OCD, 
as suggested from previous research where some patients 
appear treatment-resistant to NAC over others.71) The 
maximum dose of NAC used across these studies is 3,000 
mg/day, which may consolidate previous research involv-
ing this dose, however, will not explore if a higher dose 
may be more effective in severe and chronic presentations 
of OCD or OCRD. The study of Sarris et al. attempts to re-
cruit a wider patient demographic, which may incorporate 
a range of treatment histories, including treatment naïve 
patients. This may provide the first insight into NAC effi-
cacy as a monotherapy. Unfortunately, one study 
(Pittenger et al.) has been terminated due to lack of partic-
ipants and funding for the trial.
DISCUSSION
To our knowledge, this is the first review specifically 
exploring the use of NAC in the treatment of OCD and 
OCRD. With an increase in the amount of clinical trials 
and case reports published since 2006, and more ongoing 
research, this indicates NAC to be a relatively new poten-
tial therapy for these conditions, and one of growing 
interest. However, of the few studies in the area (n=11) 
over half are case reports and results are promising but 
inconsistent. This highlights the need for further rigorous 
clinical research. Of note, NAC has been used ad-
junctively with various pharmacotherapies, particularly 
SSRI medication, without negative interactions and ap-
pears to show benefit in some treatment refractory 
patients. Promising new research highlights the potential 
of NAC to potentiate the antidepressant activity of certain 
SSRIs and tricyclic antidepressants.82) However, NAC is 
yet to be investigated as a monotherapy for OCD or 
OCRD and thus, its ability to exert therapeutic effects 
when administrated on its own is yet to be identified.
From the reviewed literature, the preliminary evidence 
supports the use of NAC in presentations of moder-
ate-severity OCD and OCRD. Doses of 2,400-3,000 
mg/day for a minimum of eight weeks (preferably 12 
weeks) may be adequate for exerting an initial therapeutic 
effect. However, even this treatment regime in moderate 
presentations of OCD and OCRD showed varied response 
rates as demonstrated in the trials of Grant et al.39) and 
Afshar et al.68), where almost half of the participants with-
in the treatment group did not display a full clinical 
response. In addition, two other studies failed to demon-
strate a therapeutic effect of NAC.71,76) However, the se-
verity of OCD symptoms in patients in the case series of 
Van Ameringen et al.71) was of greater degree than Afshar 
et al.68) Additionally, they were an older patient group 
with a high lifetime prevalence of OCD and various 
co-morbidities including tourettes, MDD, substance 
abuse, TTM, attention deficit hyperactivity disorder, and 
excoriation. This case series also lacked rigorous clinician 
oversight. Furthermore, NAC was not administered for a 
time frame that has been necessary to achieve therapeutic 
effects in other psychiatric trials.39,61,68) Insignificant ef-
fects of NAC over placebo have been identified in a pedia-
tric TTM clinical trial.76) However, the pediatric pop-
ulation may have been heavily influenced by clinical in-
terventions and psychoeducation regarding TTM, as sug-
gested by improvements in both the treatment and control 
group. Due to various methodological limitations asso-
ciated with the case series and pediatric clinical trial, the 
potential of NAC for OCD and OCRD cannot be 
discounted. Differences in disease severity, chronicity, 
co-morbidities, as well as neurobiological heterogeneity 
may account for varied treatment response rates amongst 
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these studies. It is imperative that future research explores 
NAC’s efficacy in larger clinical trials, which include a 
varied cohort of symptom severity and age. Dose escala-
tion studies and trials with longer durations (i.e., more 
than 12 weeks), would be beneficial to determine if more 
severe and complex presentations, particularly of OCD, 
would respond to NAC.
Continued, comprehensive investigations into the neu-
robiology of obsessive-compulsive and related disorders, 
as well as a clearer understanding of the pharmacokinetics 
of NAC may help to elucidate more specific therapeutic 
indications for NAC within clinical presentations of OCD 
and OCRD. Knowledge of the in vivo mechanisms of ac-
tion of NAC in OCD and OCRD are also lacking. Given 
what is known about NAC’s ability to modulate gluta-
mate, it may be patients with glutamate abnormalities who 
are responsive to NAC. If so, the therapeutic efficacy for 
NAC in both of these disorders suggests that the parallels 
between OCD and OCRD clinical presentations may be, 
in some cases, the result of underlying glutamate dysregu-
lation, as well as oxidative stress, the latter either as a 
causative factor or consequence of the disease process. 
However, from the reviewed literature, the role of gluta-
mate in the pathophysiology of patients responsive to 
NAC cannot be determined. Future clinical trials which 
incorporate measures to determine glutamate abnormal-
ities, such as magnetic resonance imaging (MRI) or func-
tional MRI brain imaging would be of great utility in ad-
dressing whether NAC has the ability to directly modulate 
activity in the regions most heavily implicated in the 
pathogenesis of these disorders.
NAC appears to be extremely well tolerated, with mini-
mal adverse effects reported. Mild gastrointestinal effects 
appear to be the most common symptom-flatulence 
(which ceased after two weeks of NAC supplementation), 
headache, skin rash, diarrhea and nausea and vomiting of 
mild-moderate intensity.67,73,76,78,81) However, nausea and 
vomiting was also experienced in the placebo group of one 
particular trial, and was not evident in others.68) Other 
clinical trials have demonstrated no adverse effects, and 
NAC has shown to be very well tolerated in doses up to 
8,000 mg/day in other areas of research.39,71,83) This sug-
gests there may be scope for a higher dose of NAC to be in-
vestigated in OCD and OCRD patients who appear resistant 
to doses of 3,000 mg/day used in the discussed research. 
In summation, although NAC appears effective in the 
majority of the published research, data is inconclusive, 
and it is yet to be rigorously investigated. Factors such as 
larger cohorts, higher doses and longer treatment may pro-
vide more definitive answers regarding the benefits of 
NAC for OCD and OCRD. The chronic and debilitating 
nature of these disorders, coupled with the current lack of 
reliable pharmacotherapies, strongly justifies the need for 
treatment alternatives. The emergence of promising, yet 
preliminary NAC research highlights this nutraceutical as a 
potential treatment option that warrants further investigation.
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